Skip to main content

CapitalGainsReport: Thursday’s OTC Watchlist (EVFM, EPAZ, NWBO, VDRM)

--News Direct--

Investors often look for opportunities in the stock market that won't require a significant capital outlay while still having the potential for large wins. The OTC markets offer investors plenty of opportunity with stocks under $1 that offer that potential.

While these stocks may be considered riskier investments due to their lower price points, they also have the potential for significant growth and profitability, making them an attractive option for investors looking to diversify their portfolio and potentially achieve substantial gains.

Though the overall market saw a slight downturn on Wednesday, these four stocks saw a great deal of market activity and should be on your watchlist Thursday: EVFM, NWBO, EPAZ, and VDRM.

Evofem Biosciences Inc. (OTC: EVFM) is a company that is developing and commercializing innovative products to address women's sexual and reproductive health needs. Their first FDA-approved product is Phexxi, a hormone-free contraceptive vaginal gel that can be used on demand.

Yesterday, March 22, EVFM finished at a price of 0.0365, representing an increase of 32.73% from its previous trading session.

EVFM has been implementing measures to lower its operating expenses, with the goal of reaching break-even cash flow by the year's end in 2023. On March 21, EVFM announced that it had successfully reduced its payroll expenses by 39% through these measures.

On March 15, EVFM stockholders approved an amendment to the company’s Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the company’s common stock by a ratio of not less than 1 for 20 and not more than 1 for 125 at any time on or prior to March 15, 2024.

Epazz, Inc. (OTC: EPAZ) is a mission-critical provider of drone technology, blockchain mobile apps, and cloud-based business software solutions. On Tuesday, EPAZ announced that company spinoff ZenaDrone, Inc., recently visited a California airbase and conducted flight demonstrations and presentations.

The company representatives met with top military officials to discuss how ZenaDrone 1000 could work within their operations. Because of the success of the visit, ZenaDrone, Inc. is now preparing for flight demonstrations and presentations at multiple air bases.

At these future presentations and demonstrations, military pilots will take control of the drone to evaluate its ease of use and portability, while maintenance crew will determine how to integrate the drone into operations.

The demonstrations are scheduled tentatively for June, subject to the completion of necessary paperwork and regulations. The company is in the process of registering additional drones with the FAA and securing the required insurance.

Pay close attention as EPAZ seems to be moving in the right direction with the government contract path that they are taking. CEO Shaun Passley, PhD, said, “We received amazing feedback on ZenaDrone 1000 and are very pleased to be moving to the next stage with the USAF.”

The news of the successful visit to the California air base is just one in a string of recent victories for EPAZ. This most recent update follows last month's news regarding ZenaDrone signing up a U.S. defense contractor to partner with on submitting a SBIR Phase II proposal. This partnership will help ZenaDrone fast-track the Phase II submission process, which includes a U.S. government customer.

The ZenaDrone 1000 has already received positive feedback from various industries, including agricultural, oil and gas, wildfire management, and civil engineering. The recent military use case has further reinforced the drone's capabilities.

ZenaDrone plans to improve its artificial intelligence capabilities by adding autonomous navigation in unmapped areas, deep learning algorithms, and dual-use features to cater to both commercial and military drone applications. EPAZ has the potential to take off benefit from this development.

Northwest Biotherapeutics Inc. (OTC: NWBO) is a biotech firm that specializes in creating personalized immune therapies for cancer patients. The company's products are built around DCVax, a technology that activates dendritic cells to mobilize a patient's own immune system to attack cancer cells.

Monday, NWBO and Advent BioServices, a reputable contract development and manufacturing organization based in the UK, jointly announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved and issued a MIA license for the commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.

This MIA is one of the first licenses for commercial manufacturing of cell therapy products in the U.K.; according to NWBO, there are only two other such licenses, one of which is also a newly granted facility.

Northwest Biotherapeutics Inc. (OTC:NWBO) closed at a price of 0.6401, representing a slight increase of 0.80% from its previous trading session.

ViaDerma, Inc. (OTC: VDRM) is a specialty pharmaceutical company in the United States that develops and markets pharmaceutical products and licenses its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product, Vitastem, is a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.

On March 22, VDRM's stock price surged by 29.41% following news that the company had submitted an application for their planned minoxidil hair regrowth product for FDA registration status approval.

The new hair regrowth product will incorporate ViaDerma's proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route).

In addition, the company announced that it has chosen Nupelo as the brand name for the product. The FDA registration process is expected to be completed within a few weeks, and the company is optimistic about the prospects of its new product. Nupelo is expected to be ready to go to market and available to purchase online by the end of Q2 2023.

"Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both," said ViaDerma’s President & CEO, Dr. Chris Otiko.

CapitalGainsReport is a financial website for investors seeking nanocap and microcap opportunities. We cover macroeconomic news, sector plays, company news, technical analysis, market action alerts, and catalysts that drive price action. Please visit our site at

Contact Details

Mark McKelvie

+1 585-301-7700

Company Website

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.